← Back to news
🔴 BreakingNewsFDAThursday, March 19, 2026 · March 19, 2026

FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide

WHY IT MATTERS

FDA announcement relevant to rare disease patients and caregivers.

The U.S. Food and Drug Administration today approved a new higher dose (7.2 mg) of Wegovy (semaglutide) injection for weight loss and long-term maintenance of weight loss for certain adult patients.

View FDA Announcement →
Read the original at FDA ↗
FDA ApprovalTreatment

Related conditions

IgG4-related sclerosing cholangitisPrader-Willi-like syndromeHigh-grade dysplasia in patients with Barrett esophagusSTING-associated vasculopathy with onset in infancyGenetic obesity

Related news

FDA
FDA Approves XTORO
XTORO (FINAFLOXACIN) received FDA approval.…
FDA
FDA Approves IOPIDINE
IOPIDINE (APRACLONIDINE HYDROCHLORIDE) received FDA approval.…
FDA
FDA Approves SABRIL
SABRIL (VIGABATRIN) received FDA approval.…
FDA
FDA Approves IOPIDINE
IOPIDINE (APRACLONIDINE HYDROCHLORIDE) received FDA approval.…